A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 4 SUPPL. 1, 2003, Pages

  Rose, Carsten ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Aromatase inhibitors; Breast cancer; Estrogen receptor; First line therapy; Second line therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HEART FAILURE; HORMONAL THERAPY; HUMAN; HYPERTENSION; LUNG EMBOLISM; METASTASIS; REVIEW; SIDE EFFECT; STROKE; SWEATING; THROMBOEMBOLISM; VAGINA BLEEDING; WEIGHT GAIN;

AMINOGLUTETHIMIDE; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; FEMALE; HUMANS; MEGESTROL ACETATE; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN; TRIAZOLES;

EID: 0043092398     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200308001-00003     Document Type: Review

References (21)

1. Buzdar AU. A summary of second-line randomized studies of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;79:109-14.
2. Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs 2002;62:957-66.
3. Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-9.
4. Johnston SRD, Saccani-Joti G, Ebbs SR, et al. ER expression at relapse on tamoxifen predicts for second-line endocrine response in advanced breast cancer [Abstract 6.3]. Br J Cancer 1997; 75(suppl 1):16.
5. Johnston SRD, Smith IE, Dowsett M. Place of aromatase inhibitors in the endocrine therapy of breast cancer. In: Miller WR, Santen RJ, eds. Aromatase inhibition and breast cancer. New York: Marcel Dekker, 2001:29-49.
6. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982;5:155-60.
7. Smith IE, Harris AL, Morgan M, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized crossover trial. BMJ (Clin Res Ed) 1981;283:1432-4.
8. Santen RJ, Misbin RI. Aminoglutethimide: review of pharmacology and clinical use. Pharmacotherapy 1981;1:95-120.
9. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998;9:639-45.
10. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-66.
11. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-61.
12. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000-11.
13. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142-52.
14. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-411.
15. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer [Abstract 131]. Proc Am Soc Clin Oncol 2002;21:34a.
16. Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol 1988;27:721-8.
17. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:2234-44.
18. Jones S, Vogel C, Arkhipov A, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 1999;17:3418-25.
19. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19: 3808-16.
20. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-7.
21. Jonat W, Howell A, Blomquist C, et al. A randomized trial comparing two dosages of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32:404-12.